| Literature DB >> 21030565 |
Abstract
In this issue of Blood, Berentsen and coworkers describe a high response rate which is durable in some patients who receive combination fludarabine and rituximab for chronic cold agglutinin disease (CAD). If confirmed, this is a significant advance in therapy for a frequently difficult clinical problem.Entities:
Year: 2010 PMID： 21030565 DOI： 10.1182/blood-2010-07-297523
Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113